0000000000084350
AUTHOR
Samuel Limat
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Purpose Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the presence of the primary tumor could be involved in less efficient antitumor activity of antiangiogenic agents, but no clinical data currently support this hypothesis. Methods We performed a retrospective analysis of factors associated with overall survival (OS) in a study cohort of 409 mCRC patients. Univariate and multivariate Cox proportional hazard regression models were used to assess the infl…
Bon usage des anticancéreux dans les tumeurs solides : impact des référentiels de bon usage
Resume Introduction Le bon usage des medicaments anticancereux est un enjeu majeur de pilotage des etablissements de sante. L’elaboration de referentiels de bon usage (RBU) est un dispositif specifique de notre systeme de sante. Objectif L’objectif principal de notre travail est de confronter les pratiques therapeutiques aux RBU. L’objectif secondaire est d’evaluer l’impact des RBU sur les recours « hors referentiel » en comparaison d’une etude similaire realisee en 2004. Patients et methode L’etude est realisee entre le 01/07/2008 et le 31/03/2009 sur deux centres de reference en cancerologie. Elle inclut 2289 patients representant 3187 recours a une molecule anticancereuse financee en sus…
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM
Abstract Background. Peripheral blood stem cell (PBSC) collection prior to high dose chemotherapy for autologous transplantation (ASCT) is a standard of care, and an attractive alternative to the use of bone marrow cells, for transplantation in Multiple Myeloma (MM). The optimal methodology for mobilizing PBSC has yet to be defined, both G-CSF and GM-CSF can be used; although, the stimulatory effect may be more pronounced when given after high dose cyclophosphamide (usually administered at a dose of 1.5 to 6g/m2 IV for one to two days) and use of Plerixafor, a CXCR4 antagonist (Mozobil®). The latter 2 options are preferred, overall, in France. Indeed, it was shown that the most recent combi…
Appropriate cytotoxic drugs usages in solid tumors: Impact of appropriate use referentials
Summary Background The appropriate use of anticancer drugs is at major stake of steering health facilities. French health authorities have specifically elaborated evidence-based principles and guidelines on good practice for the management of anticancer drugs called “referentiels de bon usage” (RBU in French). Objectives The primary aim of the survey is to confront therapeutic practices and PGU. The secondary objective is to evaluate the impact of PGU on “outside the prescribing guidelines” therapeutic use, as compared with a similar study conducted in 2004. Patients and methods The survey was conducted from 1st July 2008 to 31st March 2009 at two reference centers in cancer research, and i…